A systematic review shows estrogen therapy may help with menopausal hair loss. A new non-hormonal drug GS1-144 targets hot flash mechanisms directly. And experts are exploring why ADHD diagnoses are rising in menopausal women as estrogen decline affects dopamine and focus.

Key Takeaways:

• Estrogen therapy shows promise for menopausal hair loss, but results vary and early treatment seems to work better

• GS1-144, a neurokinin 3 receptor antagonist, significantly reduced hot flash frequency and severity in a phase 2 trial

• More women in their 40s and 50s are being diagnosed with ADHD for the first time, possibly linked to declining estrogen affecting dopamine

• Focus and attention issues that persist despite menopause treatment may warrant an ADHD evaluation

Sources & References:

• Menopause and hair loss in women: Exploring the hormonal transition (https://pubmed.ncbi.nlm.nih.gov/40318238/) - PubMed

• Neurokinin 3 receptor antagonism for menopausal hot flashes (https://pubmed.ncbi.nlm.nih.gov/37541194/) - PubMed

• ADHD Diagnoses May Be Rising In Menopausal Women (https://www.huffingtonpost.co.uk/entry/adhd-menopause-link-explained_uk_69ea1477e4b0bb584bc96158) - HuffPost

Listen with full show notes: https://hotflasher.com/episodes/2026-04-27-research-roundup

Have a menopause story to share? We'd love to hear it:

https://hotflasher.com/share

---

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.